Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/08/25
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/28/25
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract CancerGlobeNewsWire • 04/21/25
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology ForumGlobeNewsWire • 04/02/25
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract CancerGlobeNewsWire • 04/01/25
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract CancerGlobeNewsWire • 03/31/25
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/27/25
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 02/10/25
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's WhyZacks Investment Research • 01/31/25
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 12/10/24
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerGlobeNewsWire • 12/10/24
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary CancerSeeking Alpha • 12/09/24
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewsWire • 12/02/24
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)Zacks Investment Research • 11/21/24
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/24
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/08/24
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 10/04/24
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/07/24
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual MeeGlobeNewsWire • 05/23/24